THANK YOU FOR SUBSCRIBING
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
ReGelTec is developing the next-gen of interverbal disc implants to alleviate lower back pain. The company’s core offering, HYDRAFIL™, is a percutaneous disc augmentation treatment— delivered via a 17-gauge needle—to treat degenerative disc disease. The HYDRAFIL™ solution is heated and injected into the nucleus of an intervertebral disc. As the HYDRAFIL™ cools, it solidifies as a homogenous solid mass between the vertebrae to eliminate pain. Since the implant is a hydrogel that has mechanical properties similar to the normal disc tissues, it helps restore the natural biomechanics of the disc and improve spinal alignment.![]()
ReGelTec is developing the next-generation of spinal implants to percutaneously treat lower back pain
Share this Article:
Tweet
|
Company
ReGelTec
Headquarters
Baltimore, MD
Management
Bill Niland, President and CEO and Dr. Anthony M. Lowman, Co-Founder & CTO
Description
ReGelTec, a pre-clinical medical device company, is developing the next generation of spinal implants for lower back pain and degenerative disc disease. The company’s HYDRAFIL™solution is heated and injected into the nucleus of an intervertebral disc.As the HYDRAFIL™ cools it solidifies as a homogenous solid mass between the vertebrae to eliminate pain. Since the implantis a hydrogelthat has mechanical properties similar to the normal disc tissues,it helps restore the natural biomechanics of the disc and improve spinal alignment. With this commitment to developing innovative healthcare products, ReGelTecwill start its clinical trial in Colombia by early 2020
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info